XML 68 R50.htm IDEA: XBRL DOCUMENT
v3.24.1

Research, Consulting and Supply Agreements (Details Narrative) | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Sep. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | Sep. 30, 2022 USD ($) | Apr. 30, 2022 USD ($) | Mar. 31, 2023 USD ($) Integer | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2017 Integer | Oct. 31, 2023 USD ($) shares
Research and development expense |  |  |  |  |  | $ 10,939,000 | $ 6,990,000 |  |
Amarex Clinical Research LLC [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 4,290,000 | 2,272,000 |  |
Research and development expense excluding acquired in process cost |  |  | $ 6,400,000 | $ 8,400,000 |  |  |  |  |
Development cost |  |  | 125,000 | $ 1,000,000 |  | 6,600,000 |  |  |
Estimated lives |  |  |  | 4 years 7 months 6 days |  |  |  |  |
Invigilators cost |  |  | $ 4,400,000 |  |  |  |  |  |
Amarex Clinical Research LLC [Member] | Pancreatic Cancer [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 600,000 | 1,691,000 |  |
Amarex Clinical Research LLC [Member] | Post COVID [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 3,690,000 | 581,000 |  |
Jubilant HollisterStier [Member] |  |  |  |  |  |  |  |  |
Number of units manufactured | Integer |  |  |  |  |  |  |  | 16,000 |
Additional number of vials | Integer |  |  |  |  | 27,900 |  |  |  |
Inventory work in process and raw materials |  |  |  |  | $ 1,432,000 |  |  |  |
Jubilant HollisterStier [Member] | Research Consulting and Supply Agreements [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 1,432,000 | 79,000 |  |
Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 363,000 |  |  |
Erasmus [Member] | Joint Clinical Study Agreement [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  | $ 200,000 |  |  |  |  |  |  |
Erasmus [Member] | Jjoint Clinical Study Agreement [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 100,000 |  |  |
Azenova Sales International [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 75,000 |  |  |
Stock options, aggregate intrinsic value |  |  |  |  |  |  |  |  | $ 30,000
Stock options, vested | shares |  |  |  |  |  |  |  |  | 360,000
Alcami [Member] |  |  |  |  |  |  |  |  |
Research and development expense | $ 30,000 |  |  |  |  | 65,000 | 18,000 |  |
Clinical Studies [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 6,014,000 | 4,070,000 |  |
Manufacturing and Engineering [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 3,220,000 | 1,241,000 |  |
Quality Control [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 1,271,000 | 1,236,000 |  |
Regulatory [Member] |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | $ 434,000 | $ 443,000 |  |

X
- Definition Number of vials. + References No definition available. + Details
Name: | AIM_NumberOfVials
Namespace Prefix: | AIM_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and development expense cost estimated lives. + References No definition available. + Details
Name: | AIM_ResearchAndDevelopmentExpenseCostEstimatedLives
Namespace Prefix: | AIM_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Units manufactured. + References No definition available. + Details
Name: | AIM_UnitsManufactured
Namespace Prefix: | AIM_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost of maintenance incurred and directly related to good produced and service rendered. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_CostMaintenance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 932 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-10(c)(7)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1 + Details
Name: | us-gaap_DevelopmentCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_InventoryWorkInProcessAndRawMaterials
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_PancreaticCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_PostCOVIDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_JubilantHollisterStierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_ResearchConsultingAndSupplyAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_PharmaSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_MasterServiceAgreementAndQualityAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_ErasmusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_JointClinicalStudyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIM_JjointClinicalStudyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_AzenovaSalesInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIM_AlcamiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIM_ClinicalStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIM_ManufacturingAndEngineeringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIM_QualityControlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIM_RegulatoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |